Sarcopenia and MASLD: novel insights and the future
Issued Date
2025-01-01
Resource Type
ISSN
17595029
eISSN
17595037
Scopus ID
2-s2.0-105020990050
Journal Title
Nature Reviews Endocrinology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Reviews Endocrinology (2025)
Suggested Citation
Liu C.H., Zeng Q.M., Kim W., Kim S.U., Younossi Z.M., Targher G., Byrne C.D., Mantzoros C.S., Charatcharoenwitthaya P., Leclercq I.A., Romero-Gómez M., Tang H., Zheng M.H. Sarcopenia and MASLD: novel insights and the future. Nature Reviews Endocrinology (2025). doi:10.1038/s41574-025-01197-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113051
Title
Sarcopenia and MASLD: novel insights and the future
Author's Affiliation
Harvard Medical School
Université Catholique de Louvain
West China School of Medicine/West China Hospital of Sichuan University
Yonsei University College of Medicine
Seoul National University College of Medicine
Hospital Universitario Virgen del Rocío
Southampton General Hospital
Siriraj Hospital
Severance Hospital
The First Affiliated Hospital of Wenzhou Medical University
Seoul Metropolitan Government - Seoul National University Borame Medical Center
Università di Verona Scuola di Medicina e Chirurgia
Ospedale Sacro Cuore Don Calabria
Inova Health System
Center for Liver Disease
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province
Université Catholique de Louvain
West China School of Medicine/West China Hospital of Sichuan University
Yonsei University College of Medicine
Seoul National University College of Medicine
Hospital Universitario Virgen del Rocío
Southampton General Hospital
Siriraj Hospital
Severance Hospital
The First Affiliated Hospital of Wenzhou Medical University
Seoul Metropolitan Government - Seoul National University Borame Medical Center
Università di Verona Scuola di Medicina e Chirurgia
Ospedale Sacro Cuore Don Calabria
Inova Health System
Center for Liver Disease
Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province
Corresponding Author(s)
Other Contributor(s)
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle mass and muscle function. These conditions are closely connected, and metabolic syndrome and its associated metabolic factors have a crucial role in their relationship. Metabolic syndrome considerably affects the risk and progression of MASLD and sarcopenia and promotes their development through various mechanisms. This Review explores the epidemiological link between MASLD and sarcopenia and the effect of metabolic syndrome and its components on both conditions, summarizing current treatment strategies and emerging evidence. To effectively manage both MASLD and sarcopenia, it is crucial to incorporate the five metabolic risk factors of metabolic syndrome into risk assessment and treatment strategies. Future research should continue to investigate the mechanisms linking metabolic syndrome, MASLD and sarcopenia. Establishing standardized definitions of sarcopenia for patients with MASLD and developing personalized treatment strategies through precision medicine will improve diagnosis, interventions and overall patient outcomes.